A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in
patients with depression. The primary objective is to evaluate the efficacy and safety of
Saredutant 100 mg once daily compared to placebo in the prevention of relapse of depressive
symptoms in outpatients with major depressive disorder who achieved an initial response to 12
weeks of open-label treatment with Saredutant.